Publicaciones en colaboración con investigadores/as de Hospital Clínico Universitario Lozano Blesa (15)

2024

  1. Indicators to evaluate quality of care in head and neck cancer in Spain

    Clinical and Translational Oncology, Vol. 26, Núm. 5, pp. 1089-1097

2022

  1. Date of admission during covid-19 pandemic impacted patient outcomes in addition to the higher efficacy of tocilizumab plus high-dose corticosteroid therapy compared to tocilizumab alone

    Journal of Clinical Medicine, Vol. 11, Núm. 1

  2. PPAR-γ Gene Expression in Human Adipose Tissue Is Associated with Weight Loss After Sleeve Gastrectomy

    Journal of Gastrointestinal Surgery, Vol. 26, Núm. 2, pp. 286-297

2021

  1. Correction to: SEOM clinical guidelines for the treatment of head and neck cancer (2020) (Clinical and Translational Oncology, (2021), 23, 5, (913-921), 10.1007/s12094-020-02533-1)

    Clinical and Translational Oncology

  2. Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial

    Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 764-772

2018

  1. SEOM clinical guidelines for the treatment of head and neck cancer (2017)

    Clinical and Translational Oncology, Vol. 20, Núm. 1, pp. 75-83

2017

  1. Could the Addition of Cetuximab to Conventional Radiation Therapy Improve Organ Preservation in Those Patients With Locally Advanced Larynx Cancer Who Respond to Induction Chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 Study

    International Journal of Radiation Oncology Biology Physics, Vol. 97, Núm. 3, pp. 473-480

2013

  1. The highly prevalent BRCA2 mutation c.2808_2811del (3036delACAA) is located in a mutational hotspot and has multiple origins

    Carcinogenesis, Vol. 34, Núm. 11, pp. 2505-2511

2012

  1. In answer to: "comments to SEOM clinical guidelines for the treatment of thyroid cancer" by Garcilaso Riesco-Eizaguirre et al

    Clinical and Translational Oncology

2011

  1. SEOM clinical guidelines for the treatment of thyroid cancer

    Clinical and Translational Oncology, Vol. 13, Núm. 8, pp. 574-579

2010

  1. Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment

    British Journal of Cancer, Vol. 102, Núm. 12, pp. 1687-1691

  2. SEOM clinical guidelines for the treatment of head and neck cancer

    Clinical and Translational Oncology, Vol. 12, Núm. 11, pp. 742-748

  3. SEOM clinical guidelines for the treatment of nasopharyngeal carcinoma

    Clinical and Translational Oncology

2009

  1. Spanish Society of Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer patients

    Clinical and Translational Oncology, Vol. 11, Núm. 11, pp. 727-736

2002

  1. Estudio de la astenia tumoral: Constituci-acon del grupo ASTHENOS

    Revista Clinica Espanola, Vol. 202, Núm. 10, pp. 525-528